Long-term safety of facilitated subcutaneous immunoglobulin: Insights from a postauthorization safety study in primary immunodeficiency diseases (PID)

被引：0
|
作者：
Rubinstein, Arye [1 ,2 ]
Patel, Niraj C. [3 ]
Wedner, H. James [4 ]
Wasserman, Richard L. [5 ]
Gupta, Sudhir [6 ]
Fielhauer, Katharina [7 ]
Chavan, Shailesh [8 ]
Yel, Leman [9 ]
机构：
[1] Albert Einstein Coll Med, Bronx, NY 10467 USA
[2] Montefiore Hosp, Bronx, NY USA
[3] Atrium Hlth, Levine Childrens Hosp, Charlotte, NC USA
[4] Washington Univ, Barnes Jewish Hosp, Sch Med, St Louis, MO USA
[5] Allergy Partners North Texas Res, Dallas, TX USA
[6] Univ Calif Irvine, Irvine, CA USA
[7] Baxalta Innovat GmbH, Vienna, Austria
[8] Shire US Inc, Lexington, MA USA
[9] Baxalta US Inc, Cambridge, MA USA
来源：
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM | 2021年 / 26卷 / 03期
关键词：
facilitated subcutaneous immunoglobulin; real-world data; safety study; chronic inflammatory demyelinating polyradiculoneuropathy;
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
65
引用
收藏
页码：334 / 335
页数：2
相关论文
共 50 条
  • [31] Long-Term Efficacy, Adverse Events, and Tolerability of Recombinant Human Hyaluronidase -Facilitated Subcutaneous Infusion of Immunoglobulin G (FSCIG) in Patients Aged <18 Years with Primary Immunodeficiency Diseases (PID)
    Wasserman, Richard L.
    Melamed, Isaac
    Stein, Mark
    Kobrynski, Lisa
    Gupta, Sudhir
    Engl, Werner
    McCoy, Barbara
    Leibl, Heinz
    Yel, Leman
    JOURNAL OF CLINICAL IMMUNOLOGY, 2017, 37 : S53 - S54
  • [32] Efficacy and Safety of Self-Administered Subcutaneous Immunoglobulin in Polish Children with Primary Immunodeficiency Diseases
    Stelmach, I.
    Bal, K.
    Sobocinska, A.
    Zaczeniuk, M.
    Podsiadlowicz-Borzecka, M.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 : S304 - S304
  • [33] Efficacy and Safety of IgPro20, a Subcutaneous Immunoglobulin, in Japanese Patients with Primary Immunodeficiency Diseases
    Hirokazu Kanegane
    Kohsuke Imai
    Masafumi Yamada
    Hidetoshi Takada
    Tadashi Ariga
    Martin Bexon
    Mikhail Rojavin
    Wilson Hu
    Midori Kobayashi
    John-Philip Lawo
    Shigeaki Nonoyama
    Toshiro Hara
    Toshio Miyawaki
    Journal of Clinical Immunology, 2014, 34 : 204 - 211
  • [34] Efficacy and Safety of IgPro20, a Subcutaneous Immunoglobulin, in Japanese Patients with Primary Immunodeficiency Diseases
    Kanegane, Hirokazu
    Imai, Kohsuke
    Yamada, Masafumi
    Takada, Hidetoshi
    Ariga, Tadashi
    Bexon, Martin
    Rojavin, Mikhail
    Hu, Wilson
    Kobayashi, Midori
    Lawo, John-Philip
    Nonoyama, Shigeaki
    Hara, Toshiro
    Miyawaki, Toshio
    JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 (02) : 204 - 211
  • [35] Long-term efficacy, safety, and tolerability of recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin (Ig) (fSCIG; HyQvia(®)) in immunodeficiency diseases: real-life data from a monocentric experience
    Francesca Angelotti
    Riccardo Capecchi
    Daiana Giannini
    Ornella Mazzarella
    Valeria Rocchi
    Paola Migliorini
    Clinical and Experimental Medicine, 2020, 20 : 387 - 392
  • [36] Efficacy and Safety of Facilitated Subcutaneous Immunoglobulin in Pediatric Patients with Primary Immunodeficiency Disease: Interim Analysis of a Phase 3 Study in the USA
    Patel, Niraj
    Walter, Jolan
    Wasserman, Richard
    Rubinstein, Arye
    Atkinson, T. Prescott
    Shepherd, Meagan
    Greco, Erin
    Russo-Schwarzbaum, Sara
    Saeed-Khawaja, Shumyla
    Mccoy, Barbara
    Yel, Leman
    JOURNAL OF CLINICAL IMMUNOLOGY, 2022, 42 (SUPPL 1) : S50 - S51
  • [37] Efficacy and safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10% in US pediatric patients with primary immunodeficiency disease
    Patel, Niraj
    Walter, Jolan
    Wasserman, Richard
    Rubinstein, Arye
    Atkinson, T. Prescott
    Shepherd, Meagan
    Greco, Erin
    Russo-Schwarzbaum, Sharon
    Duff, Kimberly
    Mccoy, Barbara
    Chu, Liang-Hui
    Li, Zhaoyang
    Yel, Leman
    CLINICAL IMMUNOLOGY, 2023, 250 : 148 - 149
  • [38] Assessing hyaluronidase-facilitated subcutaneous immunoglobulin 20% (fSCIG 20%) pharmacokinetics, safety and tolerability in primary immunodeficiency diseases: phase 2/3 study design
    LWasserman, Richard
    Leavis, Helen
    Nagy, Andras
    Carrasco, Paz
    Anderson-Smits, Colin
    McCoy, Barbara
    Bauer, Alexander
    Chu, Liang-Hui
    Freedman, Immanuel
    Li, Zhaoyang
    CLINICAL IMMUNOLOGY, 2024, 262
  • [39] Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% in Patients With Primary Immunodeficiency Diseases: Interim Analysis of Adverse Events in a Global Post-Authorization Safety Study
    Rubinstein, Arye
    Bridges, Tracy A.
    Wedner, H. James
    McNeil, Donald
    Wasserman, Richard L.
    Tachdjian, Raffi
    Stryk, Steven V.
    Tarpay, Martha M.
    Fielhauer, Katharina
    Leibl, Heinz
    Yel, Leman
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 143 (02) : AB117 - AB117
  • [40] Long-term efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% (cutaquig®) in the treatment of patients with primary immunodeficiencies
    Kobayashi, Roger H.
    Litzman, Jiri
    Melamed, Isaac
    Mandujano, J. Fernando
    Kobayashi, Ai Lan
    Ritchie, Bruce
    Geng, Bob
    Atkinson, T. Prescott
    Rehman, Syed
    Hoeller, Sonja
    Turpel-Kantor, Eva
    Kreuwel, Huub
    Speer, J. C.
    Gupta, Sudhir
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2022, 210 (02): : 91 - 103
12345